score_bin	sensitive_predictive_implication	resistance_predictive_implication	prognostic_predictive_implication	feature_type	feature	alteration_type	alteration	tumor_f	total_coverage	exac_af	exac_common	clinvar	sensitive_score_bin	sensitive_therapy_name	sensitive_therapy_strategy	sensitive_therapy_type	sensitive_description	sensitive_citation	sensitive_url	resistance_score_bin	resistance_therapy_name	resistance_therapy_strategy	resistance_therapy_type	resistance_description	resistance_citation	resistance_url	prognostic_score_bin	favorable_prognosis	prognostic_description	prognostic_citation	prognostic_url	number_germline_mutations_in_gene	validation_total_coverage	validation_tumor_f	validation_detection_power	feature_display	preclinical_efficacy_observed	patient_id	tumor_sample_barcode	normal_sample_barcode
Putatively Actionable	Guideline	Guideline		Copy Number	AR	Amplification				0.0	0.0		Putatively Actionable	Abiraterone	Antiandrogen	Hormone therapy	Androgen receptor activation may predict sensitivity to second generation androgen deprivation or direct androgen inhibitors.	National Comprehensive Cancer Network. Prostate Cancer NCCN Evidence Blocks (Version 3.2016). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/prostate_blocks.pdf	Putatively Actionable	Abiraterone	Antiandrogen	Hormone therapy	Androgen receptor activation is a potential mechanism of recurrence of prostate cancer during androgen deprivation therapy.	National Comprehensive Cancer Network. Prostate Cancer NCCN Evidence Blocks (Version 3.2016). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/prostate_blocks.pdf						0				AR Amplification		SC_9058	SC_9058-Tumor	
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Nonsense	p.Y64*	0.1037	135.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098													0	405.0	0.0049	1.0	SMARCA4 p.Y64* (Nonsense)		SC_9058	SC_9058-Tumor	SC_9058-Normal
Investigate Actionability	Inferential			Mutational Signature	COSMIC Signature 3	version 2	0.309						Investigate Actionability	Platinum	Platinum-based chemotherapy	Chemotherapy	Responders to platinum based chemotherapy exhibit COSMIC signature 3 (HR signature) mutations in pancreatic cancer.	Alexandrov LB, Nik-zainal S, Siu HC, Leung SY, Stratton MR. A mutational signature in gastric cancer suggests therapeutic strategies. Nat Commun. 2015;6:8683.	https://doi.org/10.1038/ncomms9683													0				COSMIC Signature (version 2) 3 (31%)		SC_9058		
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R282W	0.8092	346.0	1.6e-05	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0.0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	0	702.0	0.9544	1.0	TP53 p.R282W (Missense)		SC_9058	SC_9058-Tumor	SC_9058-Normal
Investigate Actionability		Clinical evidence		Somatic Variant	AR	Missense	p.D297Y	0.0109	9147.0	8e-06	0.0									Investigate Actionability	Abiraterone	Antiandrogen	Hormone therapy	Androgen receptor mutation may predict resistance to second generation androgen deprivation or direct androgen inhibitors.	Chen EJ, Sowalsky AG, Gao S, et al. Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors. Clin Cancer Res. 2015;21(6):1273-80.	https://doi.org/10.1158/1078-0432.CCR-14-1220						0	3394.0	0.027999999999999997	1.0	AR p.D297Y (Missense)		SC_9058	SC_9058-Tumor	SC_9058-Normal
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.R531M	0.4286	280.0	0.0	0.0																Investigate Actionability	0.0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	0	25.0	0.44	0.9986	SETBP1 p.R531M (Missense)		SC_9058	SC_9058-Tumor	SC_9058-Normal
Investigate Actionability			Inferential	Aneuploidy	Whole genome doubling																						Investigate Actionability	0.0	WGD was associated with adverse survival pan-cancer in patients with advanced disease and in cancers with heterogeneous clinical outcomes, even following the development of metastasis.	Bielski CM, Zehir A, Penson AV, et al. Genome doubling shapes the evolution and prognosis of advanced cancers Nat Genet. 2018; 50(8):1189-1195.	https://doi.org/10.1038/s41588-018-0165-1	0						SC_9058		
Investigate Actionability	Clinical evidence			Somatic Variant	MLH3	Missense	p.I185V	0.2414	290.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596													0	20.0	0.3	0.7448	MLH3 p.I185V (Missense)		SC_9058	SC_9058-Tumor	SC_9058-Normal
Investigate Actionability	Preclinical			Rearrangement	RAF1	Fusion	GOLGA4--RAF1			0.0	0.0		Investigate Actionability	Sorafenib	RAF inhibition	Targeted therapy	Rearrangements in BRAF are rare but may result in dependencies that can be targeted with RAF and MAP2K1 inhibitors.	Palanisamy N, Ateeq B, Kalyana-sundaram S, et al. Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. Nat Med. 2010;16(7):793-8.	https://doi.org/10.1038/nm.2166													0				GOLGA4--RAF1 Fusion	0.0	SC_9058		
Investigate Actionability		Clinical evidence		Copy Number	CRKL	Deletion				0.0	0.0									Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	CRKL amplification was observed in an EGFR inhibitor resistant tumor after researchers observed that cells from gefitinib-sensitive cell line (HCC827) overexpressing CRKL became resistant to gefitinib relative to controls.	Cheung HW, Du J, Boehm JS, et al. Amplification of CRKL induces transformation and epidermal growth factor receptor inhibitor resistance in human non-small cell lung cancers. Cancer Discov. 2011;1(7):608-25.	https://doi.org/10.1158/2159-8290.CD-11-0046						0				CRKL Deletion		SC_9058	SC_9058-Tumor	
Biologically Relevant				Rearrangement	AR	Fusion	AR--PTMA			0.0	0.0																					0				AR--PTMA Fusion		SC_9058		
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.R469Q	0.2063	223.0	0.0	0.0																					0	1792.0	0.0028	1.0	COL1A1 p.R469Q (Missense)		SC_9058	SC_9058-Tumor	SC_9058-Normal
Biologically Relevant				Copy Number	MAPK1	Deletion				0.0	0.0																					0				MAPK1 Deletion		SC_9058	SC_9058-Tumor	
Biologically Relevant				Microsatellite Stability	Supporting variants		PRDM2 p.E1261del (Deletion)																									0				Supporting variants: PRDM2 p.E1261del (Deletion)		SC_9058		
Biologically Relevant				Mutational Signature	COSMIC Signature 1	version 2	0.234																									0				COSMIC Signature (version 2) 1 (23%)		SC_9058		
